Subscribe to AfterDawn's weekly newsletter.
Novagali Pharma Announces the Update of its "Document De Base" With the French Securities Market Authority ("Autorité des marchés financiers" - AMF)
EVRY, France, September 14 /PRNewswire/ --
- Not for Distribution in the United States, Canada or Japan
Novagali Pharma, an emerging ophthalmic pharmaceutical
company, announces that the update of its document de base was filed on
September 12th , 2007 to the Autorité des marchés financiers (AMF).
This update concerns half-yearly IFRS accounts ended on June
30th, 2007. The document de base also announces that the product candidate
Vekacia(R) was filed on July 27, 2007 with the European Agency for the
Evaluation of Medicinal Product (EMEA), for marketing approval for the
treatment of Vernal Keratoconjunctivitis ("VKC").
The document de base, registered on July 18, 2007 under number
I.07-132 and its update are available free of charge from Novagali Pharma, 1
rue Pierre Fontaine, Bâtiment Genavenir IV, 91000 Evry, France, on the AMF
website (http://www.amf-france.org) and on the Novagali Pharma website
(http://www.novagali.com).
The public attention is drawn to the chapter 4 of the document
de base, entitled << Risk Factors >>.
This press release, the information contained herein, the
registration document and the actualization of the registration document
which is referred to, do not constitute an offer to sell or a solicitation of
an offer to buy or subscribe for shares in Novagali Pharma in any country. No
offer to sell shares in Novagali Pharma has been made, nor will be made,
prior to the official approval by the Autorité des marchés financiers (AMF)
of a prospectus comprising the registration document, its actualization which
is the subject of this press release, and an offering prospectus which will
be submitted to the AMF at a future date.
Shares of Novagali Pharma may not be sold in the United States
of America (as defined under Regulation S of the U.S. Securities Act of 1933,
as amended) without registration or an exemption from registration under the
U.S. Securities Act of 1933, as amended. There will be no registration of all
or part of the offering referred to in this press release in the United
States nor any public offering of Novagali Pharma securities in the United
States. This press release may not be distributed, either directly or
indirectly, in the United States and does not constitute an offer to sell
securities in the United States.
There is no offer in the United Kingdom. In the United
Kingdom, this information is directed only at investment professionals within
the meaning of Article 19(1) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 of the United Kingdom (the Order) or persons
who fall within Article 49(1) of the Order, or any other person to whom
Novagali Pharma may legally transmit an invitation or solicitation to invest
under the Order.
About Novagali Pharma : http://www.novagali.com
Novagali Pharma is an emerging ophthalmic pharmaceutical
company based in the Génopôle biocluster in Evry (France), that develops
innovative products for all segments of the eye. Thanks to its proprietary
technology platforms Novasorb(R) and Eyeject(R), the company has developed a
broad pipeline of 8 innovative products addressing main ocular conditions as
well as orphan diseases. Most advanced products include Vekacia(R), an orphan
product for treatment of vernal keratoconjunctivitis, Cationorm(R), a CE mark
product for dry eye relief, and Nova22007, a product for the treatment of
moderate-to-severe dry eye syndrome. Founded in 2000, Novagali Pharma has
raised a total amount of Euro 44 million in 3 series of financing.
